Mystery caller study on emergency contraception in Germany!

By João L. Carapinha

June 20, 2023

Researchers examined immediate availability, pricing, and counseling aspects of oral emergency contraception in Berlin pharmacies.
Results included:

✅ Ulipristal acetate prices ranged from €15.95 to €42.95 (median €35.00)
✅ Levonorgestrel prices ranged from €10.60 to €32.49 (median €22.00)

Great access, but high price ranges pose challenges. A comparison app could help minimize costs. Pharmacy staff training is essential for providing “adequate” counseling.

Reference url

Recent Posts

ivonescimab lung cancer treatment
       

Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer

🚀 🌍 Ivonescimab’s NMPA approval for PD-L1+ NSCLC reshapes oncology!

This chemo-free bispecific antibody outperforms pembrolizumab, boosting PFS/OS in the HARMONi-2 trial. Its dual-action mechanism sets a new standard, driving urgency for market access and policy strategies. Discover why this breakthrough matters for global NSCLC care (and more indications in the pipeline).

Dive into the full article [here] (https://www.akesobio.com/en/media/akeso-news/250426/).

#SyenzaNews #oncology #HealthcareInnovation #PharmaInnovation #NSCLC

CDC hepatitis lab closure
         

Assessing Risks and Opportunities: The Impact of the CDC Hepatitis Lab Closure

🚨 Is the abrupt closure of the CDC’s only hepatitis lab leaving the U.S. vulnerable during an ongoing outbreak?

This article looks into the ramifications of the CDC hepatitis lab closure amid federal layoffs, questioning the impact on outbreak detection and public health. With the lab’s unique capabilities being irreplaceable, what does this mean for our response to hepatitis outbreaks?

Explore the critical insights and implications for our public health infrastructure.

#SyenzaNews #HealthcareInnovation #HealthEconomics #PublicHealth

peanut oral immunotherapy
        

Promising Results for Peanut Oral Immunotherapy

🌟 Ready to change the conversation on peanut allergies?

A recent study from the University of Virginia shines a light on peanut oral immunotherapy (epOIT), revealing that 90% of young children achieved effective desensitization with minimal side effects. This compelling research advocates for early intervention, potentially transforming how we manage this prevalent food allergy.

Dive into the full article to explore how adopting this approach could reshape health policies and enhance quality of life for affected families.

#SyenzaNews #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.